Previously, patentees could legally extend the duration of a patent unlimitedly, but the government's plan is to promote it up to 'up to 14 years'. According to the pharmaceutical industry on the 21st, the Korean Intellectual Property Office recently prepared an amendment to the Patent Act to reform the system for the duration of drug patent rights. The amendment is expected to be submitted to the National Assembly through legislative acts.

In the current drug patent term extension system, there is no separate upper limit (cap). In addition to the essential patent period of 20 years, it extends the time taken for clinical trials and approval and approval of drugs. In other words, the duration of drug p